# A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Source: https://onco.cc/trials/nct04414163/  
OnCo record `nct04414163` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IMC-001 in peripheral T-cell lymphomas, run by ImmuneOncia Therapeutics Inc., active and no longer recruiting.

## Summary

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type is a phase 2 interventional study registered as NCT04414163 by ImmuneOncia Therapeutics Inc., with 23 participants enrolled, started 2020-10-27 and due to reach its primary completion in 2024-07-23. Interventions recorded: IMC-001.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04414163
- Phase: 2
- Setting: An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
- Sponsor: ImmuneOncia Therapeutics Inc.
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT04414163: https://clinicaltrials.gov/study/NCT04414163

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04414163.json